Caracterização clínica e imunoistoquímica dos adenomas clinicamente não-funcionantes de hipófise: clinical features and immunohistochemistry

Clinically non-functioning pituitary adenomas do not produce clinical signs of hormonal hypersecretion. Therefore, signs and symptoms will depend on the mass effect of these adenomas over the central nervous system. Their etiopathogeny is complex and their development is probably influenced by several factors, such as hypothalamic hormones (GHRH), growth factors (FGF), proliferation factors (PCNA, and KI-67), protein P53 and the proto-oncogene c-erb-B2. OBJECTIVE: 1) Determining the clinical features of a population of 117 patients treated for clinically non-functioning pituitary adenoma (age, sex, tumor size, number of surgical procedures, development of hormonal deficiency and hyperprolactinemia). 2) Identifying, after the patients had been clinically characterized, those with clinically non-functioning adenomas with positive immunohistochemistry for hypophyseal hormones (PRL, LH, FSH, GH, TSH and ACTH). 3) Determining if the immunohistochemistry of this population was positive for the cellular proliferation factor Ki-67, protein P53 and protein C-erb-B2 and establishing a correlation with tumor size and tumor invasiveness. This will help in the evaluation of the prognostic value of these proliferation factors. 4) Confronting the results of immunohistochemistry using a standard block with the results of immunohistochemistry using a tissue micro-array. METHOD: Study of the clinical features of 117 patients with clinically non-functioning pituitary adenoma (age, sex, tumor size, number of surgical procedures, development of hormonal deficiency and hyperprolactinemia). Immunohistochemical study (HE r=-0.181, p=0.397; r=0.272, p=0.199, respectively). The tissue micro-array also did not demonstrate a correlation between positive immunohistochemistry for Ki-67 and C-erb-B2 and tumor size, but it showed a statistically significant correlation between a positive immunohistochemistry for p53 and tumor size (r=-0.696; p=001). CONCLUSION: The biological behavior of the clinically non-functioning adenoma is similar for both sexes. The larger the tumor the greater the number of surgical procedures needed. Hormonal deficiency also becomes more significant as the size of the tumor increases. This paper suggests that a positive immunohistochemistry for p53 is negatively correlated to tumor size, thus demonstrating that it has a predictor value. However, a positive immunohistochemistry for Ki-67 and protein C-erb-B2 does not seem to be a prognostic factor for clinically non-functioning pituitary adenomas, as is the case with other neoplasias.

[1]  S. Chevillard,et al.  Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer , 2005, Breast Cancer Research and Treatment.

[2]  J. Lawson,et al.  Microcysts and Breast Cancer: A Study of Biological Markers in Archival Biopsy Material , 2002, Breast Cancer Research and Treatment.

[3]  J. Rutka,et al.  Genetic Basis of Pituitary Adenoma Invasiveness: A Review , 2001, Journal of Neuro-Oncology.

[4]  I. Christensen,et al.  Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy , 2000, Breast Cancer Research and Treatment.

[5]  D. Lüdecke,et al.  Proliferation Markers in Different Types of Clinically Non-Secreting Pituitary Adenomas , 1999, Pituitary.

[6]  L. Beckman,et al.  Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. , 2004, European journal of cancer.

[7]  B. Scheithauer,et al.  Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. Report of two cases. , 2003, Journal of neurosurgery.

[8]  D. Jablons,et al.  Malignant mesothelioma does not demonstrate overexpression or gene amplification despite cytoplasmic immunohistochemical staining for c-Erb-B2. , 2003, Archives of pathology & laboratory medicine.

[9]  S. Tsutsui,et al.  Prognostic significance of the coexpression of p53 protein and c-erbB2 in breast cancer. , 2003, American journal of surgery.

[10]  P. Karakitsos,et al.  Image analysis (DNA ploidy) and expression of c-erb B-2 and p53 in imprint smears of breast cancer. , 2003, European journal of gynaecological oncology.

[11]  C. Morrison,et al.  C-erb B2 (Her2/ neu) Is Neither Overexpressed nor Amplified in Hepatic Neoplasms , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[12]  N. Ferreira,et al.  Expression of p53 protein in pituitary adenomas. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[13]  S. Tsutsui,et al.  Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer , 2002, Breast cancer.

[14]  G. Maira,et al.  Anterior pituitary adenomas in patients aged more than 65 years: analysis of growth fraction (using the MIB-1 monoclonal antibody) and of clinical features in comparison to younger patients , 2002, Clinical Neurology and Neurosurgery.

[15]  Marcin Schmidt,et al.  Immunohistochemical assay of p53, cyclin D1, c-erbB2, EGFr and Ki-67 proteins in HPV-positive and HPV-negative cervical cancers. , 2002, Folia histochemica et cytobiologica.

[16]  K I Bland,et al.  Molecular Biomarkers for Breast Cancer Prognosis: Coexpression of c-erbB-2 and p53 , 2001, Annals of surgery.

[17]  J. Royds,et al.  Mdm2 and the p53 pathway in human pituitary adenomas , 2001, Clinical endocrinology.

[18]  A. Lewiński,et al.  Correlation between PCNA expression and AgNOR dots in pituitary adenomas , 2001, Endocrine pathology.

[19]  R. Delcelo,et al.  [Pituitary adenomas: relationship between invasiveness and proliferative cell nuclear index]. , 2000, Arquivos de neuro-psiquiatria.

[20]  T. Kokunai,et al.  Bromocriptine-induced apoptosis in pituitary adenoma cells: relationship to p53 and bcl-2 expression , 1999, Journal of Clinical Neuroscience.

[21]  L. Blevins,et al.  Aggressive pituitary tumors. , 1998, Oncology.

[22]  R. Seruca,et al.  P53 in breast carcinomas: association between presence of mutation and immunohistochemical expression using a semiquantitative approach. , 1998, Pathology, research and practice.

[23]  S. Atkin,et al.  A comparison of proliferation indices in human anterior pituitary adenomas using formalin-fixed tissue and in vitro cell culture. , 1997, Journal of neurosurgery.

[24]  C. Christov,et al.  Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: correlation with proliferative activity and prognostic index. , 1997, General & diagnostic pathology.

[25]  S. Melmed,et al.  Genetic basis of endocrine disease: pituitary tumor pathogenesis. , 1997, The Journal of clinical endocrinology and metabolism.

[26]  K. Takakura,et al.  [The relationship between cell proliferation activity and secretory activity in pituitary adenoma--a review of 63 cases]. , 1996, No to shinkei = Brain and nerve.

[27]  J. Xiao,et al.  Molecular and cellular responses to DNA damage in a murine pituitary adenoma cell line , 1996, Molecular and Cellular Endocrinology.

[28]  Y. Yonemasu,et al.  Dural invasion and proliferative potential of pituitary adenomas. , 1996, Neurologia medico-chirurgica.

[29]  S. Lightman,et al.  p53 gene mutations in pituitary adenomas: rare events , 1994, Clinical endocrinology.

[30]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[31]  A. Klibanski,et al.  Clinical review 45: Clinically nonfunctioning pituitary adenomas. , 1993, The Journal of clinical endocrinology and metabolism.

[32]  S. Syrjänen,et al.  Immunohistochemical demonstration of c-erb B-2 oncoprotein expression in female breast cancer and its prognostic significance. , 1991, Anticancer research.

[33]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.